The National Institutes of Health Clinical Center in Bethesda, MD, recently announced a Phase 1 clinical trial of a novel influenza vaccine that has begun inoculating healthy adult volunteers.
This innovative study will evaluate the safety of the whole-virus BPL-1357 vaccine candidate’s ability to prompt immune responses.
BPL-1357 was developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID).
Read More
